Contents

Experimental Studies

* Review: Novel Therapeutic Approaches for Targeting Tumor Angiogenesis. A.G. LINKOUS, E.M. YAZLOVITSKAYA (Bethesda, MD; Nashville, TN, USA) ................................................................. 1

Growth Effect of Neutrophil Elastase on Breast Cancer: Favorable Action of Sivelestat and Application to Anti-HER2 Therapy. M. NAWA, S. OSADA, K. MORIMITSU, K. NONAKA, M. FUTAMURA, Y. KAWAGUCHI, K. YOSHIDA (Gifu, Japan) ................................................................. 13


The Cyano Fluorescent Protein Nude Mouse as a Host for Multicolor-coded Imaging Models of Primary and Metastatic Tumor Microenvironments. A. SUETSUGU, M.K. HASSANEIN, J. REYNOSO, Y. OSAWA, M. NAGAKI, H. MORIWAKI, S. SAJI, M. BOUVET, R.M. HOFFMAN (San Diego, CA, USA; Gifu, Japan) ...... 31

Color-coded Real-time Subcellular Fluorescence Imaging of the Interaction between Cancer and Host Cells in Live Mice. K. YAMAUCHI, Y. TOMO, N. YAMAMOTO, K. HAYASHI, H. KIMURA, H. TSUCHIYA, K. TOMITA, M. BOUVET, R.M. HOFFMAN (San Diego, CA, USA; Fuku; Okina; Kanazawa, Ishikawa, Japan) ................................................................. 39

Effects of Vitamin D-binding Protein-derived Macrophage-activating Factor on Human Breast Cancer Cells. S. PACINI, T. PUNZI, G. MORUCCI, M. GULISANO, M. RUGGIERO (Firenze, Italy) ....................... 45

Contents continued on the back cover
Editorial Board

B. B. Aggarwal  
Cytokine Research Laboratory, Department of Experimental Therapeutics, University of Texas M.D. Anderson  
Cancer Center, Houston, TX, USA

J. P. Armand  
Institut Claudius Regaud, Toulouse, France

V. I. Avramis  
Division of Hematology/Oncology, Childrens Hospital, Los Angeles, CA, USA

R. C. Bast  
Department of Translational Research, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

G. Bauer  
Abteilung Virologie, Institut für Medizinische Mikrobiologie und Hygiene, Universität Freiburg, Germany

E. E. Baulieu  
INSERM U488 and College de France, Le Kremlin-Bicetre, France

Y. Becker  
Department of Biochemistry, Faculty of Medicine, Hebrew University of Jerusalem, Ein Kerem, Jerusalem, Israel

E. J. Benz, Jr.  
Dana-Farber Cancer Institute, Boston, MA, USA

J. Bergh  
Department of Clinical and Molecular Medicine, Radiumhemmet, Karolinska Institute, Stockholm, Sweden

D. D. Bigner  
Department of Pathology, Duke University Medical Center, Durham, NC, USA

A. Böcking  
Institute for Cytology, University of Düsseldorf, Germany

G. Bonadonna  
Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy

F. T. Bosman  
Institute of Pathology, University of Lausanne, Switzerland

G. Broich  
Gruppo Policlinico di Monza, Monza, Italy

J. M. Brown  
Department of Radiation Oncology, Stanford Medical Center, Stanford, CA, USA

Ø. S. Bruland  
Department of Medical Oncology-Radiotherapy, Norwegian Radium Hospital, Oslo, Norway

M. M. Burger  
Novartis, Basel, Switzerland

M. Carbone  
Cancer Research Center of Hawaii, Honolulu, HI, USA

J. Carlsson  
Department of Biomedical Radiation Sciences, Uppsala University, Sweden

A. F. Chambers  
Department of Oncology, London Regional Cancer Center, London, Ontario, Canada

P. Chandra  
Abt. für Molekularbiologie, Klinikum Wolfgang Goethe-Universität, Frankfurt am Main, Germany

L. Cheng  
Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA

J.-G. Chung  
Department of Biological Science and Technology, China Medical University, Taichung, Taiwan, ROC

E. De Clercq  
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium

W. De Loecker  
Department of Biochemistry, Katholieke Universiteit Leuven, Belgium

W. Den Otter  
VUMC, Department of Urology, Amsterdam, The Netherlands

E. P. Diamandis  
Department of Pathology and Laboratory Medicine, Mount Sinai Hospital, Toronto, Ontario, Canada

G. Th. Diamandopoulos  
Department of Pathology, Harvard Medical School, Boston, MA, USA

W. Ebert  
Thoraxclinic HD-Rohrbach, Heidelberg, Germany

D.W. Felsher  
Division of Oncology, Stanford University School of Medicine, Stanford, CA, USA

J. A. Fernandez-Pol  
Metalloproteomics, LLC, Chesterfield, MO, USA

I. J. Fidler  
Department of Cancer Biology, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA

A.P. Fields  
Department of Cancer Biology, College of Medicine, Mayo Clinic, Jacksonville, FL, USA

G. Gabbiani  
Department of Pathology, University of Geneva, Switzerland

R. Ganapathi  
Department of Clinical Pharmacology, Taussing Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA

A. F. Gazdar  
Hamon Center for Therapeutic Oncology Research, University of Texas Southeastern Medical Center, Dallas, TX, USA

J.H. Geschwind  
Interventional Radiology Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA

A. Giordano  
Sbarro Institute for Cancer Research, Temple University, Philadelphia, PA, USA

G. Gitsch  
Department of Gynecology and Obstetrics, University of Freiburg, Germany

R. H. Goldfarb  
Sophon Therapeutics, Inc., Princeton, NJ, USA

J. W. Gorrod  
Toxicology Unit, John Tabor Laboratories, University of Essex, Colchester, Essex, UK

S. Hammarström  
Department of Immunology, University of Umeå, Sweden

I. Hart  
Centre for Tumour Biology, Institute of Cancer and CR-UK Clinical Centre, Bart’s and The London, Queen  
Mary’s School of Medicine and Dentistry, London, UK

I. Hellström  
Harborview Medical Center, Seattle, WA, USA

continued
continued
Experimental Studies